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Abstract: 24 
Background: The annual Muslim pilgrimage has the potential of increase risk for 25 
acquisition of Neisseria meningitidis. Here, we evaluate the Hajj impact on the 26 
prevalence of N. meningitidis carriage in a paired and non-paired cohort of pilgrims.  27 
Secondary objectives were to calculate the compliance with recommended vaccination.   28 
Methods: This a prospective paired (arriving and departing), non-paired arriving and 29 
non-paired departing cohort study with the collection of nasopharyngeal samples at the 30 
start and the end of the Hajj.  31 
Results: The study included unpaired arriving pilgrims at King Abdul Aziz International 32 
Airport (N=1055), unpaired departing cohort (N=373), and a paired cohort (N=628) who 33 
were tested on arrival and departure. Meningococcal vaccination was received by all 34 
pilgrims, 98.2% received quadrivalent polysaccharide vaccine (ACWY), and 1.8% 35 
received meningococcal quadrivalent conjugate vaccine (MCV4).  Only 1.61% and 36 
23.03% received pneumococcal and influenza vaccines, respectively.   Of the 1055 37 
arriving unpaired pilgrim, 36 (3.4%) tested positive for nasopharyngeal carriage of N. 38 
meningitidis, and 24 (66.7%) of these were serogroup B, the remainder were non-39 
groupable. Haemophilus influenza was detected among 45 (4.3%), and 11 (1%) carriers 40 
were positive for both N. meningitidis and H. influenzae. Out of 373 in the unpaired 41 
departing cohort, 6 (1.61%) tested positive for N. meningitidis, and 34 (9.1%) were 42 
positive for H. influenzae. Of the 628 paired cohort pilgrims, 36 (5.7%) pilgrims were 43 
positive for N. meningitidis at arrival and 16 (2.5%) pilgrims were positive after the hajj.   44 
Conclusion: This the largest study of the epidemiology of N.  meningitidis among 45 
pilgrims. The study showed a significant difference in the carriage between pilgrims from 46 
high endemicity and other pilgrims with a predominance of serogroup B.  The continued 47 
use of ciprofloxacin as prophylactic antibiotics should be reconsidered as well as the 48 
consideration to add serogroup B as a required vaccination.   49 
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Introduction 68 
Meningococcal disease is a major cause of morbidity and mortality worldwide [1].  69 
Meningococcal disease occurs at a rate of 0.5 -10 cases per 100.000 and may reach a rate 70 
of 1,000 in epidemic countries [2]. Neisseria meningitidis is classified into 12 serogroups, 71 
Only 6 serogroup (A, B, C, W, Y, X) are responsible for most invasive meningococcal 72 
disease [3].  Meningococcal disease is the most common presentation of invasive 73 
meningococcal infection and causes a substantial burden and death among all age groups 74 
[4]. Mass gatherings are associated with outbreaks of respiratory infection diseases 75 
including meningococcal disease [5–9]. In 1987, the first international meningococcal 76 
disease outbreak following the Hajj occurred and was caused by N. meningitidis 77 
serogroup A [10–12], and serogroup W135 [13]. The prevalence of asymptomatic N. 78 
meningitidis carriage increases increased more than 80% and contributed to outbreaks 79 
during Hajj in 1987 and 2000-2001 [9,10]. Due to these outbreaks, the Ministry of Health 80 
in Saudi Arabia adopted  the mandatory vaccination for all hajj Hajj pilgrims, annual 81 
vaccination campaigns for all the residents living in the area near the pilgrimage site and 82 
mandatory oral ciprofloxacin prophylaxis for all the pilgrims coming from sub-Saharan 83 
African meningitis belt countries [1,10,14–16].   84 
 Mass gatherings continue to draw larger crowds from around the Globe [13]. These 85 
events offer a great potential for a health legacy through intense periods of unprecedented 86 
focus and funding for improvement in health systems. However, these events also pose 87 
several significant public health challenges within the host country and abroad [17].  88 
Meningococcal disease has been associated with the Hajj.  Of factors that increase 89 
acquisition of N. meningitidis is the Hajj pilgrimage due to crowding and the gathering of 90 
millions in a small place [8,9]. Taking effective preventive measures by the Saudi 91 
Ministry of Health, in recent years, curtailed the development of meningococcal 92 
outbreaks since the W outbreak in 2000 [7,9,10]. Of those preventive measures, 93 
mandatory vaccination of domestic and international pilgrims is required using 94 
quadrivalent meningococcal vaccine and as well as the administration of a single dose of 95 
ciprofloxacin as chemoprophylaxis against N. meningitidis carriage to pilgrims from sub-96 
Saharan African meningitis belt [14]. These practices are based on the evidence of 97 
distribution pattern of N. meningitidis in the world. Outbreaks in sub-Saharan Africa were 98 
caused by serogroup C, W and X meningococcal but most of epidemics were due to 99 
serogroup A [18].  Meningococcal serogroup W caused an outbreak in Saudi Arabia 100 
among pilgrims during Hajj season 2000 and spread to contacts after returning back to 101 
home countries [6,19]. Epidemics related to serogroup B meningococcal disease were 102 
reported in Norway and Cuba since 1976 [20]. Late in 1980 group B meningococcal 103 
disease spreading from Cuba to São Paulo in Brazil and in 2000 in New Zealand [21,22].  104 
Prophylactic ciprofloxacin can decrease the carriage rate from 8.1% to 0% before and 105 
after the Hajj [23]. The recent epidemiologic changes of N. meningitidis infection in 106 
Africa and other parts of the world; the improvement in vaccination practices among 107 
pilgrims; and recent development of conjugate vaccine permit the policy Maker in 108 
Ministry of Health, KSA, to re-evaluate aspects of N. meningitidis epidemiology and to 109 
re-assess the prevention measures that applied during hajj.   110 
In this study, we evaluate the Hajj impact on the prevalence of N. meningitidis carriage in 111 
pilgrims. Secondary objectives were to calculate the compliance with recommended 112 
vaccination and to re-evaluate the recommendations of a chemoprophylaxis applied 113 
during Hajj. 114 
Methods: 115 
Study Area: King Abdul Aziz International Airport (KAAIA) in Jeddah occupies an area 116 
of 105 km² and is located 70 kilometers west of the holy city of Makkah, where the 117 
pilgrims perform the religious rituals. There are three passenger terminals: the North 118 
terminal handles all foreign air carriers, the South terminal handles local flights, and the 119 
Hajj Terminal handles pilgrims traveling to Makkah. The KAAIA Hajj terminal is the 120 
gateway to Makkah and is designed in the form of tents occupying an area of 465,000 121 
m2. KAAIA can receive about 80,000 pilgrims in 36 hours during the hajj Hajj season. 122 
Twelve teams from  preventive medicine consisted of physicians, nurses and health 123 
inspectors and were distributed in each arrival hall to assess pilgrims, check the 124 
vaccination cards, administer chemoprophylaxis  single dose of ciprofloxacin tablets) for 125 
pilgrims arriving from the sub-Saharan meningitis belt countries and perform other 126 
preventive measures, in accordance with international health regulation for pilgrimage  127 
posted yearly by Ministry of health , Saudi Arabia [14,15,24].  128 
Mina: is a small city located inside a valley in the province of Makkah, about 8 km to the 129 
east of the Holy city of Makkah. It covers an area of approximately 20 km². There are 130 
more than 100,000 air-conditioned tents in Mina providing temporary accommodation for 131 
three million pilgrims. The tents are constructed of fibber glass coated with Teflon in 132 
order to ensure high resistance to fire. In these tents Hajj pilgrims stay overnight for five 133 
days as part of the Hajj season.  134 
Ethical Approval: 135 
The study was approved by the institutional review board (IRB) of King Fahd Medical 136 
City, Riyadh, Saudi Arabia. 137 
Study Population: 138 
The study included unpaired cohort of arriving pilgrims at KAAIA (N=1055), unpaired 139 
departing cohort (N=373), and a paired cohort (N=628) who were tested on arrival and 140 
departure.  Arriving pilgrims were recruited at KAAIA on October 2-October 7, 2014, 141 
and departing pilgrims were sampled after performing the hajj Hajj in Mina tents 142 
(October 16-October 24, 2014). Nationality of pilgrims was chosen based on the level of 143 
meningococcal meningitis endemicity of respective countries. The annual incidence per 144 
100,000 population of >10 cases, 2–10 cases, and < 2 cases represent high, moderate, and 145 
low endemicity, respectively [25,26].   To obtain adequate sample size, only countries 146 
with more than 5,000 pilgrims were included in the study. We included pilgrims who 147 
were 18 years of age and older and verbal consent was obtained. If a pilgrim refused to 148 
participate then next pilgrims was asked to take part in the study. 149 
Laboratory testing: 150 
Nasopharyngeal swabs were collected in accordance with WHO guideline, from pilgrims 151 
upon arrival and departure. Samples were collected in a charcoal swab with transport 152 
media, and were transported in cold boxes at temperature 2-8
o
 C, and were sent to KAIA 153 
laboratory within 2 hours of collection at arrival time and to Hira’a General hospital in 154 
Makkah laboratory at departure time. Identification of Neisseria species was determined 155 
by biochemical testing, polymerase chain reaction (PCR) and genotyping in Special 156 
Infectious Agent Units at King Fahd Medical Research Center of King Abdulaziz 157 
University  [27,28]. 158 
Cultures: 159 
Samples were cultured immediately using direct plating to non-selective and selective 160 
media, enriched chocolate agar and 5 % sheep blood agar plates. Samples were directly 161 
inoculated on labeled fresh culture plates and streaked for isolation with a sterile 162 
disposable loop. All plates were incubated at 36°C in humidified 5-10% CO2 incubator. 163 
Plates were examined for growth and typical colonies after 18-24 hours of incubation and 164 
again after 48 hours and were examined for colonies with consistent Neisseria 165 
morphology. All suspected Neisseria species were subculture for purity on both chocolate 166 
and sheep blood plates.   167 
Sample transportation and storage:  Frozen samples transported to Special infectious 168 
Agents Unit King Fahd Medical Research Center –Jeddah and stored at -80◦C for DNA 169 
extraction, QIAamp DNA kit(Qiagen), were used following the manufacturer’s protocol 170 
specifically developed for extraction of DNA from Pharyngeal swab and the extracted 171 
DNA was stored at -80
º
C for PCR analysis.  172 
Polymerase chain reaction (PCR) 173 
In this study we have used N. meningitidis species-specific assays ctrA considering the 174 
probes and guidelines of CDC. The capsule transport gene, ctrA, is highly conserved 175 
among isolates responsible for invasive meningococcal infections [27,29].  It is, however, 176 
not found in all carriage isolates as capsular null (cnl) meningococci are found in carriage 177 
though only very rarely cause disease in immunocompromised patients and thus are not 178 
the focus of this current study [30].   179 
In paralleled to the above RT-PCR, a dual-labelled Multiplex Real-Time PCR based FTD 180 
bacterial meningitis kit (Luxembourg) were used for detection of N. meningitidis, and 181 
Haemophilus influenzae from extracted DNA of each sample following the 182 
manufacturer’s protocol. The test is fully validated with fast-track master mix (Fast-track 183 
Diagnostics) and AgPath ID™ One-Step RT-PCR kit (life technologies™). The test 184 
contained one positive control and one negative control in each run. The 7500 fast real 185 
time PCR instrument (Applied Bio System) was used for this project. Each sample was 186 
tested individually in a single tube for the N. meningitidis, and H. influenzae.  187 
We performed genogrouping of the positive samples of N. meningitidis for the detection 188 
of A, B, C, W and Y.  In this study, we have used real time Singleplex PCR strategy to 189 
identify the six N.  meningitidis genogroups from the N. meningitidis positive samples 190 
following genogroup-specific primers and the protocol described by Wang et al [28].   191 
Results: 192 
The study included unpaired cohort of arriving pilgrims at KAAIA (N=1055), unpaired 193 
departing cohort (N=373), and a paired cohort (N=628) who were, tested on arrival and 194 
departure.   195 
Unpaired Arriving Pilgrims: 196 
Of 1055 unpaired arriving pilgrims, 23.03% (n=243) were 18-40 years, 641 (60.76%) 197 
were 41–65 years, 149 (14.12%) were ˃65 years and a mean age of 50 years.  Male 198 
constituted 63% (n=665) of this cohort.  Of those pilgrims, 25.69% (n=271) were from 199 
high endemic countries (the sub-Saharan meningitis belt), 53.2% (n=562) from medium 200 
endemic countries, and 21% (n=222) were from low endemic countries (Table 1). In 201 
relation to meningococcal vaccination, 98.2% received quadrivalent polysaccharide 202 
vaccine (ACWY), and 1.8% received meningococcal quadrivalent conjugate vaccination 203 
(MCV4) vaccination.  From the unpaired arriving pilgrims, 36 (3.4%) tested positive for 204 
N. meningitides.  The positivity rate was 8.9% among individuals from high endemic 205 
region, and 2.3% from medium endemic region (Tables 1) (P 0.0001). Out of the 36 206 
positive samples, 28 (85.71%) were male, 8 (14.29%) were female. Of the 36 N. 207 
meningitidis isolates, 24 (66.7%) were serogroup B, and the remaining were non-208 
groupable.  In addition, 45 (4.3%) were positive for H. influenzae, and 11 (1%) were 209 
positive for both N. meningitidis and H. influenzae (Table 1).   210 
Unpaired departing cohort  211 
Of 373 unpaired departing cohort, 140 (37.5%) were from the high endemicity 212 
(meningitis belt) countries, 164 (43.9%) from medium endemic countries, and 69 213 
(18.49%) from low endemic countries (Table 2). Male constituted 60% of this cohort 214 
with a mean age of 48 years.  All received meningococcal vaccines, 3% received 215 
pneumococcal conjugate vaccine and 22% received influenza vaccine.  Of the 373 216 
pilgrims, 6 (1.6%) tested positive for N. meningitides (two were N. meningitidis 217 
serogroup B and four were non-groupable).  Of the 373 pilgrims, 34 (9.1%) were positive 218 
for H. influenzae.  219 
Paired cohort results: 220 
A total of 628 paired cohort pilgrims were tested on arrival and on departure.  Out of 221 
those, 124 (19.75%) were 18 - 40 years, 384 (61.15%) were 41 - 65years, 112 (17.83%) 222 
were ˃ 65 years of age. There were 63.697% male and 36.31% female.  Of those 223 
pilgrims, 136 (21.6%) were from high endemic countries, 365 (58.1%) from medium 224 
endemic countries, and 127 (20.2%) were from low endemic countries (Table 2). All 225 
received meningococcal vaccines: 98.1% received polysaccharide meningococcal vaccine 226 
(ACWY), 1.9% received MCV4 vaccine.  In addition, 2.2% received pneumococcal 227 
conjugate vaccine and 25.6% received influenza vaccine. 228 
Out of the 16 (2.5%) pilgrims in the paired group who tested positive for N. meningitides 229 
on arrival, only one (0.15%) remained positive after the hajj.  On the other hand, eight 230 
(1.3%) tested positive on departure and out of those, only 1 (1.30.15%) was positive on 231 
arrival (P = 0.0003).  Thus, the acquisition rate (negative before and positive after) was 7 232 
(1.1%). 233 
Of the paired cohort, 17 (2.7%) tested positive for H. influenzae at arrival and only 5 234 
(0.8%) remained positive at the end of the Hajj (P =0.013).  Of those who tested negative 235 
for H. influenza at arrival, 37 (5.9%) tested positive at the end of the hajj.   236 
Comparison of N. meningitides Carriage among Arriving Pilgrims: 237 
In the unpaired arriving pilgrims, N. meningitidis was detected in 7.1% and 1.9% of those 238 
from high endemic countries and other pilgrims respectively (P = 0.001). Among the 239 
paired cohort, the rate of N. meningitidis among arriving pilgrims was 3.6% in pilgrims 240 
from high endemicity and 2.2% from other pilgrims (P =0.035), Figure 1. Of all arriving 241 
pilgrims, the carriage rate was 6.3% among pilgrims from high endemic areas compared 242 
to 2% in those from other countries (P = 0.0001) (Figure 1). 243 
Discussion: Colonization by N. meningitidis can  be a major potential source of infection 244 
[31,32]. Acquisition of N. meningitidis among pilgrims is of concern for the potential 245 
spread of this organism into the pilgrims’ home countries globally [24,33]. The rate of N. 246 
meningitidis among arriving pilgrims was low even among pilgrims coming from 247 
endemic countries (6.3%).  The risk of adverse events of chemoprophylaxis may 248 
outweigh the benefits.  Evaluation of returning pilgrims to Kuwait did not reveal any 249 
colonization among 177 participants [34]. In a study from the United States, the carriage 250 
rate of serogroup W was 0.8% among pilgrims and 0.9% among non-pilgrims and thus no 251 
prophylactic antibiotic was recommended for returning Pilgrims [35,36].  In a paired 252 
cohort group, the prevalence of N. meningitidis was 2.5% on arrival and 1.3% on 253 
departure, indicating no increase in the acquisition rate of carriage of meningococci 254 
[35,36]. The use of oral ciprofloxacin was evaluated in returning Iranian pilgrims, the 255 
carriage rates of N. meningitidis was 5.2% before and 4.6% after pilgrimage (P = 0.65) in 256 
those who did not receive ciprofloxacin compared to the carriage rate of 8.1% and zero 257 
before and after pilgrimage in those who had ciprofloxacin on return [23].  In accordance 258 
with the Saudi Ministry of Health, mandatory oral ciprofloxacin prophylaxis is given to 259 
all pilgrims coming from sub-Saharan African meningitis belt countries [1,10,14–16].   260 
In the paired cohort in this study, 2.5% pilgrims tested positive for N. meningitidis on 261 
arrival and only 0.15% of them remained positive after the hajj. Data on the possibility of 262 
increased carriage among returning pilgrims are variable. Few studies showed no increase 263 
in the carriage rate [23,37,38]. In a cohort study, the acquisition rate of N. Meningitides 264 
was 0.3% among paired cohort and 0.6% among non-paired cohort [39].  In another 265 
cohort of French Hajj pilgrims, none of them had N. Meningitides on arrival or departure 266 
[40].  A recent review indicated that carriage rates were higher in Hajj pilgrims compared 267 
to Umrah pilgrims and that most studies showed the carriage rates to be comparable to 268 
the rates in non-epidemic settings [41].  The use of antibiotics during the Hajj may reduce 269 
the carriage rate [23]. Another important finding of the study is the fact that N. 270 
meningitidis serogroup B was isolated among pilgrims. N. meningitidis serogroup B is 271 
reported in many parts of the world including  Europe, Australia, and north America 272 
[26,42]. N. meningitidis serogroup B represents 50% of all meningococcal cases and 273 
caused multiple outbreaks [43,44]. The quadrivalent meningococcal vaccine became a 274 
mandatory requirement for all pilgrims in 2001 [9,14]. A serosurvey of pilgrims showed 275 
that the majority of pilgrims were vaccinated and protected against meningococcal 276 
serogroups A, C, W, and Y [45].  There is a concern of the continued change in the 277 
epidemiology of invasive meningococcal disease and the fear of the development of 278 
outbreaks related to serogroups B or X. The availability of serogroup B N. meningitidis 279 
vaccine is an added advantage to be used in cases of outbreaks [46]. The recommendation 280 
to use this vaccine for all pilgrims would require further studies of the epidemiology of N. 281 
meningitidis in pilgrims.  282 
In conclusion, this the largest study of the epidemiology of N.  meningitidis among 283 
pilgrims. The study showed a low rate of carriage and a predominance of serogroup B.  284 
The use of ciprofloxacin as prophylactic antibiotics should be reconsidered as well as the 285 
consideration to add serogroup B as a required vaccination especially for pilgrims coming 286 
from endemic areas.  287 
  288 
 289 
 290 
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Table 1:  Characteristics and Carriage Rates of N. meningitidis and H. influenzae of Unpaired Arriving Pilgrims 
 
Number of 
Nasophary
ngeal 
swabs  
Influenza 
vaccination 
n (%) 
Pneumococcal 
vaccination  
n (%) 
Carriage 
Neisseria 
meningitidis n 
(%) 
Serogroup B, 
n (%) 
Non-
groupable,  
n (%) 
Carriage H. 
influenzae  on 
arrival, n (%) 
Carriage N. 
meningitidis and 
H. influenzae  on 
arrival, n (%) 
High Risk 
Countries 
        Nigeria 85 0 (0)  0 (0) 14(16.47) 5(5.8) 9(10.5) 2 (2.3) 2(2.3) 
Ethiopia 93 0 (0) 0 (0) 6 (6.5) 4(4.3) 2(2.1) 12 (13.1) 1(1.0) 
Tanzania  95 0 (0) 0 (0) 1 (1.0) 1(1.0) 0(0) 13 (3.1) 1 (1.0) 
Subtotal 273 (25.9) 0 (0) 0 (0) 21 (8.78) 10 (3.6) 11 (4.0) 17 (6.2) 4(1.4) 
Medium Risk 
Countries 
        India 100 4 (4.0) 0 (0) 0 (0) 0(0) 0 (0) 3(3) 0 
Pakistan 98 93 (94.89) 0 (0) 1 (1.0) 1(1.0) 0 (0) 0(0) 0 
Bangladesh 79 60 (75.94) 0 (0) 2 (2.5) 2(2.5) 0 (0) 2(2.5) 1 (1.2) 
Egypt 98 3 (3.0) 0 (0) 1 (1.02) 1(1.0) 0 (0) 4(4.0) 0 
Somalia 98 0 (0) 0 (0) 7 (7.29) 6(6.25) 1(1.4) 4(4.1) 3 (3.1) 
Subtotal 467 (44.2) 160 (34.3) 0 (0) 11 (2.3) 10 (2.1) 1 (0.1) 13 (2.8) 4 (0.8) 
Low Risk 
Countries 
        Indonesia 98 56 (57.14) 0 (0) 2 (2.0) 2(2.0) 0(0) 7(7.1) 1 (1.0) 
Malaysia 95 15 (15.78) 15 (15.7) 0 (0) 0(0) 0(0) 0(0) 0 
Albania 30 0 (0) 0 (0) 0 (0) 0(0) 0(0) 1(3.5) 0 
USA 92 5 (5.49) 2 (2.1) 2 (2.1) 2(2.1) 0 (0) 7(7.6) 2 (2.1) 
Subtotal 315 (29.9) 76 (24.1 ) 17 (5.4) 4 (1.3) 4 (1.3) 0(0) 15 (4.7) 3 (0.9) 
Grand Total 1055 236 (22.36) 17 (1.6) 36 (3.4) 24 (2.27) 12 (1.1) 45(4.2) 11(1.0) 
 
Table 2: Characteristics and Carriage Rates of N. meningitidis and H. influenzae of Paired Pilgrims 
 
Number of 
Nasopharyngeal 
swabs  
Previous 
influenza 
vaccination 
n (%) 
Previous 
pneumococcal 
vaccination, 
n (%) 
Carriage 
Neisseria 
meningitidis 
at arrival, n 
(%) 
Carriage 
Neisseria 
meningitidis 
at departure, 
n (%) 
Genogroup 
B Neisseria 
meningitidis 
at arrival, n 
(%)  
Genogroup 
B Neisseria 
meningitidis 
at 
departure, 
n (%) 
High Risk 
Countries 
       Ethiopia 64 0 (0) 0 (0) 4(6.2) 0(0) 3(4.6) 0(0) 
Tanzania  72 0 (0) 0 (0) 1(1.3) 2(2.7) 1(1.3) 2(2.7) 
Subtotal 136 (21.6) 0 (0) 0 (0) 5(3.6) 2(1.4) 4(2.9) 2(1.4) 
Medium Risk Countries 
      India 73 1(1.3) 0 (0) 0(0) 0(0) 0(0) 0(0) 
Pakistan 89 84(94.3) 0 (0) 1(1.1) 0(0) 1(1.1) 0(0) 
Bangladesh 27 18(66.6) 0 (0) 1(3.7) 1(3.7) 1(3.7) 1(3.7) 
Egypt 86 3 (3.4) 0 (0) 1(1.1) 1(1.1) 1(1.1) 1(1.1) 
Somalia 50 0 (0) 0 (0) 6(12.0) 1(0) 5(10.0) 1(2.0) 
Subtotal 325 (51.7) 106 (32.6) 1 (0) 9 (2.7) 3 (0.9) 8 (2.4) 3 (1.0) 
Low Risk 
Countries 
       Indonesia 59 34(57.6) 0 (0) 1(1.6) 0(0) 1(1.6) 0(0) 
Malaysia 68 12(17.6) 12(17.6) 0(0) 1(1.4) 0(0) 1(1.4) 
USA 40 2 (3.4) 2 (5.0) 1(2.5) 1(2.5) 1(2.5) 2(5.0) 
Subtotal 167 (26.6) 48 (28.7) 14 (8.34) 2 (1.2) 2 (1.2) 2 (1.2) 3 (1.7) 
Grand Total 628 (100) 154 (24.5) 14(2.2) 16(2.5) 8(1.2) 14(2.2) 8 (1.2) 
 Figure 1: Percentage of Arriving Pilgrims with N. meningitides based on the Study Group and Endemicity 
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